Adapting HTA To A Value-Based Approach: A Conversation With ABPI's Stephen Whitehead
The Association of the British Pharmaceutical Industry's chief executive says a focus on drug value rather than cost, and an adaptive approach to health technology assessment are approaches that would encourage pharma innovation.
You may also be interested in...
British life sciences minister George Freeman has launched ambitious plans to speed access to drugs by cutting drug development times by a third – but his plans face many hurdles.
Adaptive licensing is coming to Europe and, while it will be beneficial to patients, data exclusivity considerations may render it a double-edged sword to the innovative drug industry.
NICE has cleared a path for Bristol-Myers Squibb’s Eliquis to be included on the British National Health System, but said the data supplied were not robust enough to differentiate the drug from its competition.